PMC:7088323 / 3380-6196
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":81,"end":85},"obj":"Body_part"},{"id":"T7","span":{"begin":288,"end":293},"obj":"Body_part"},{"id":"T8","span":{"begin":800,"end":814},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma13121"},{"id":"A9","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma67480"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":288,"end":293},"obj":"Body_part"},{"id":"T6","span":{"begin":862,"end":878},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000175"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T28","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T29","span":{"begin":244,"end":252},"obj":"Disease"},{"id":"T30","span":{"begin":361,"end":369},"obj":"Disease"},{"id":"T31","span":{"begin":506,"end":514},"obj":"Disease"},{"id":"T32","span":{"begin":622,"end":630},"obj":"Disease"},{"id":"T33","span":{"begin":921,"end":936},"obj":"Disease"},{"id":"T34","span":{"begin":937,"end":957},"obj":"Disease"},{"id":"T35","span":{"begin":2012,"end":2026},"obj":"Disease"},{"id":"T36","span":{"begin":2608,"end":2616},"obj":"Disease"},{"id":"T37","span":{"begin":2618,"end":2642},"obj":"Disease"}],"attributes":[{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005833"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0001370"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0004822"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T28","span":{"begin":81,"end":85},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T29","span":{"begin":100,"end":106},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T30","span":{"begin":288,"end":293},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T31","span":{"begin":384,"end":385},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T32","span":{"begin":430,"end":432},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T33","span":{"begin":862,"end":878},"obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"T34","span":{"begin":1038,"end":1040},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T35","span":{"begin":1083,"end":1087},"obj":"http://purl.obolibrary.org/obo/CLO_0001007"},{"id":"T36","span":{"begin":1101,"end":1104},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9596"},{"id":"T37","span":{"begin":1203,"end":1205},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T38","span":{"begin":1231,"end":1233},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T39","span":{"begin":1236,"end":1238},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T40","span":{"begin":1331,"end":1333},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T41","span":{"begin":1366,"end":1368},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T42","span":{"begin":1382,"end":1386},"obj":"http://purl.obolibrary.org/obo/CLO_0001320"},{"id":"T43","span":{"begin":1382,"end":1386},"obj":"http://purl.obolibrary.org/obo/CLO_0001321"},{"id":"T44","span":{"begin":1413,"end":1415},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T45","span":{"begin":1523,"end":1528},"obj":"http://purl.obolibrary.org/obo/CLO_0001009"},{"id":"T46","span":{"begin":1667,"end":1669},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T47","span":{"begin":1672,"end":1674},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T48","span":{"begin":1686,"end":1688},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T49","span":{"begin":1719,"end":1723},"obj":"http://purl.obolibrary.org/obo/CLO_0001310"},{"id":"T50","span":{"begin":1729,"end":1733},"obj":"http://purl.obolibrary.org/obo/CLO_0001310"},{"id":"T51","span":{"begin":1737,"end":1740},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9596"},{"id":"T52","span":{"begin":1774,"end":1776},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T53","span":{"begin":1846,"end":1848},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T54","span":{"begin":1905,"end":1908},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T55","span":{"begin":1911,"end":1913},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T56","span":{"begin":1916,"end":1918},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T57","span":{"begin":1919,"end":1922},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T58","span":{"begin":1930,"end":1933},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T59","span":{"begin":1935,"end":1937},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T60","span":{"begin":1943,"end":1946},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T61","span":{"begin":1958,"end":1961},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T62","span":{"begin":1973,"end":1976},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T63","span":{"begin":1988,"end":1991},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T64","span":{"begin":2003,"end":2006},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T65","span":{"begin":2033,"end":2036},"obj":"http://purl.obolibrary.org/obo/CLO_0001053"},{"id":"T66","span":{"begin":2155,"end":2157},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T67","span":{"begin":2169,"end":2174},"obj":"http://purl.obolibrary.org/obo/CLO_0001005"},{"id":"T68","span":{"begin":2227,"end":2229},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T69","span":{"begin":2227,"end":2229},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T70","span":{"begin":2277,"end":2279},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T71","span":{"begin":2294,"end":2296},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":35,"end":46},"obj":"Chemical"},{"id":"T4","span":{"begin":2145,"end":2147},"obj":"Chemical"},{"id":"T6","span":{"begin":2227,"end":2229},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_28787"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_73422"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":826,"end":842},"obj":"Phenotype"},{"id":"T3","span":{"begin":843,"end":861},"obj":"Phenotype"},{"id":"T4","span":{"begin":862,"end":878},"obj":"Phenotype"},{"id":"T5","span":{"begin":902,"end":920},"obj":"Phenotype"},{"id":"T6","span":{"begin":921,"end":936},"obj":"Phenotype"},{"id":"T7","span":{"begin":937,"end":957},"obj":"Phenotype"},{"id":"T8","span":{"begin":2012,"end":2026},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0410397"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0031944"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002202"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0032983"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002716"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0001698"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002110"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T21","span":{"begin":0,"end":204},"obj":"Sentence"},{"id":"T22","span":{"begin":205,"end":275},"obj":"Sentence"},{"id":"T23","span":{"begin":276,"end":438},"obj":"Sentence"},{"id":"T24","span":{"begin":439,"end":559},"obj":"Sentence"},{"id":"T25","span":{"begin":560,"end":652},"obj":"Sentence"},{"id":"T26","span":{"begin":653,"end":964},"obj":"Sentence"},{"id":"T27","span":{"begin":965,"end":1100},"obj":"Sentence"},{"id":"T28","span":{"begin":1101,"end":1209},"obj":"Sentence"},{"id":"T29","span":{"begin":1210,"end":1319},"obj":"Sentence"},{"id":"T30","span":{"begin":1320,"end":1496},"obj":"Sentence"},{"id":"T31","span":{"begin":1497,"end":1597},"obj":"Sentence"},{"id":"T32","span":{"begin":1598,"end":1736},"obj":"Sentence"},{"id":"T33","span":{"begin":1737,"end":1820},"obj":"Sentence"},{"id":"T34","span":{"begin":1821,"end":1884},"obj":"Sentence"},{"id":"T35","span":{"begin":1885,"end":2037},"obj":"Sentence"},{"id":"T36","span":{"begin":2038,"end":2144},"obj":"Sentence"},{"id":"T37","span":{"begin":2145,"end":2226},"obj":"Sentence"},{"id":"T38","span":{"begin":2227,"end":2377},"obj":"Sentence"},{"id":"T39","span":{"begin":2378,"end":2442},"obj":"Sentence"},{"id":"T40","span":{"begin":2443,"end":2511},"obj":"Sentence"},{"id":"T41","span":{"begin":2512,"end":2607},"obj":"Sentence"},{"id":"T42","span":{"begin":2608,"end":2816},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
0_colil
{"project":"0_colil","denotations":[{"id":"32193638-32017661-54916","span":{"begin":1510,"end":1511},"obj":"32017661"},{"id":"32193638-32027573-54917","span":{"begin":1610,"end":1612},"obj":"32027573"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
TEST0
{"project":"TEST0","denotations":[{"id":"32193638-238-243-54916","span":{"begin":1510,"end":1511},"obj":"[\"32017661\"]"},{"id":"32193638-229-235-54917","span":{"begin":1610,"end":1612},"obj":"[\"32027573\"]"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
MyTest
{"project":"MyTest","denotations":[{"id":"32193638-32017661-29362769","span":{"begin":1510,"end":1511},"obj":"32017661"},{"id":"32193638-32027573-29362770","span":{"begin":1610,"end":1612},"obj":"32027573"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
2_test
{"project":"2_test","denotations":[{"id":"32193638-32017661-29362769","span":{"begin":1510,"end":1511},"obj":"32017661"},{"id":"32193638-32027573-29362770","span":{"begin":1610,"end":1612},"obj":"32027573"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"63","span":{"begin":667,"end":675},"obj":"Species"},{"id":"64","span":{"begin":862,"end":878},"obj":"Disease"},{"id":"65","span":{"begin":921,"end":957},"obj":"Disease"},{"id":"67","span":{"begin":622,"end":630},"obj":"Disease"},{"id":"70","span":{"begin":2529,"end":2537},"obj":"Species"},{"id":"71","span":{"begin":2591,"end":2606},"obj":"Disease"},{"id":"75","span":{"begin":2651,"end":2659},"obj":"Species"},{"id":"76","span":{"begin":2671,"end":2679},"obj":"Species"},{"id":"77","span":{"begin":2618,"end":2642},"obj":"Disease"},{"id":"86","span":{"begin":35,"end":66},"obj":"Gene"},{"id":"87","span":{"begin":68,"end":72},"obj":"Gene"},{"id":"88","span":{"begin":0,"end":10},"obj":"Species"},{"id":"89","span":{"begin":100,"end":106},"obj":"Species"},{"id":"90","span":{"begin":370,"end":378},"obj":"Species"},{"id":"91","span":{"begin":244,"end":252},"obj":"Disease"},{"id":"92","span":{"begin":361,"end":369},"obj":"Disease"},{"id":"93","span":{"begin":506,"end":514},"obj":"Disease"}],"attributes":[{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:9606"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:D010996"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D010490"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:C000657245"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"Tax:9606"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:D020518"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"Tax:9606"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"Tax:9606"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:C000657245"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"Gene:59272"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"Gene:59272"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"Tax:2697049"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"Tax:9606"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"Tax:9606"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"MESH:C000657245"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:C000657245"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SARS-CoV-2 was reported to utilize angiotensin-converting enzyme-2 (ACE2) as the cell receptor into humans [14], and firstly causing pulmonary interstitial damages and subsequent with parenchymal changes. Table 1 shows the CT manifestations of COVID-19 in published articles. Reportedly, chest CT images could manifest different imaging features or patterns in COVID-19 patients with a different time course and disease severity [18, 20]. Hereinafter, we will respectively describe each imaging feature of COVID-19 with RT-PCR confirmed cases at our hospital.\nTable 1 The occurrence rate of different CT manifestations of COVID-19 in published articles\nAuthor No. of patients CT scan GGO Consolidation GGO + consolidation Interlobular septal thickening Reticular pattern Crazy paving Air bronchogram Bronchial wall thickening Bronchiolectasis Pleural thickening Pleural effusion Subpleural line Nodule Reversed halo sign Lymphadenopathy Pericardial effusion Others\nWu et al [15] 80 S 91% (73/80) 63% (50/80) - 59% (47/80) - 29% (23/80) - 11% (9/80) - - 6% (5/80) 20% (16/80) - - 4% (3/80) 5% (4/80) -\nPan et al [16] 63 S 86% (54/63) 19% (12/63) - - - - - - - - - - 13% (8/63) - - - Fibrous stripes 17% (11/63)\nYoon et al [17] 9* M 45% (35/77) 5% (2/40) 50% (20/40) - - 10% (4/40) 21% (16/77) - - - - - - 3% (1/37) - - -\nShi et al [18] 81 S 65% (53/81) 17% (14/81) - 35% (28/81) 4% (3/81) 10% (8/81) 47% (38/81) - 11% (9/81) 32% (26/81) 5% (4/81) - 6% (5/81) - 6% (5/81) - Cystic change 10% (8/81)\nChung et al [9] 21 S 57% (12/21) 29% (6/21) 29% (6/21) - 14% (3/21) 19% (4/21) - - - - - - - - - - -\nSong et al [19] 51 S 76% (39/51) 55% (28/51) 59% (30/51) 75% (38/51) 22% (11/51) - 80% (41/51) - - - 8% (4/51) - - - 6% (3/51) 6% (3/51) -\nPan et al [20] 21 M 73% (60/82) 63% (52/82) - - - 23% (19/82) - - - - - - - - - - -\nFang et al [6] 51 S 72% (36/50) - - - - - - - - - - - - - - - -\nBernheim et al [12] 121 S 34% (41/121) 2% (2/121) 41% (50/121) - - 5% (6/121) - 12% (14/121) - - 1% (1/121) - - 2% (2/121) - - Bronchiectasis 1% (1/121)\nAi et al [21] 1014 S 46% (409/888) 50% (447/888) - 1% (8/888) 1% (8/888) - - - - - - - 3% (24/888) - - - -\nNG et al [22] 21 S 86% (18/21) 62% (13/21) 19% (4/21) - - - - - - - - - - - - - -\nLi et al [23] 83 S 98% (81/83) 64% (53/83) - 63% (52/83) 5% (4/83) 36% (30/83) 23% (19/83) - - 8% (7/83) 20% (17/83) 7% (6/83) - 8% (7/83) 5% (4/83) -\nChen et al [24] 99 S 14% (14/99) - - - - - - - - - - - - - - - -\nGuan et al [25] 1099 S 56% (550/975) - - - - - - - - - - - - - - - -\n*77 lesions in 9 patients were assessed (40 patchy to confluent lesions and 37 nodular lesions)\nCOVID-19, coronavirus disease 2019; No. of patients, number of patients; M, multiple, indicating multiple CT scans were assessed; S, single, indicating single CT scan was assessed; GGO, ground glass opacities"}